MedTrace Logo

Serum Copeptin in Cirrhotic Patients With Spontaneous Bacterial Peritonitis

NCT05401721 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 89

Last updated 2022-06-02

No results posted yet for this study

Summary

Current reports have demonstrated that copeptin predicts disease progression and prognosis in cirrhotic patients, independent of liver-specific scoring systems. To the best of our knowledge, few studies have addressed the association between copeptin and sepsis in cirrhotic patients, however, they were performed on different types of infections. Therefore, we will conduct this study with a focus on it is possible role in patients with SBP.

Conditions

  • Spontaneous Bacterial Peritonitis

Interventions

DIAGNOSTIC_TEST

Serum copeptin

Blood test

Sponsors & Collaborators

  • Sohag University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-01
Primary Completion
2021-12-01
Completion
2021-12-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05401721 on ClinicalTrials.gov